Salute e Benessere

Psoriasis Treatment & Drug Market Insights: A Guide for New & Existing Entrants…

Psoriasis: A Persistent Skin Condition Psoriasis: A Persistent Skin Condition Dive into the perplexing world of psoriasis, a chronic autoimmune skin ailment that perplexes millions of individuals worldwide, constituting 2 to 3% of the global population. Inthe United Statesalone, this enigmatic condition plagues approximately 8 million people. On a noteworthy World Psoriasis Day in 2019, an astonishing 41,164 cases came to light, primarily attributed to enigmatic disruptions in both...

Alvotech Announces Changes to the Leadership Team

Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has been appointed Alvotech's Chief Operating Officer and Hafrun Fridriksdottir is stepping down following resubmission of the Biologics License Application (BLA) for AVT02, Alvotech's proposed high-concentration interchangeable biosimilar to Humira® (adalimumab).Faysal has served as Head of...

Virbac : Declaration of the number of shares and voting rights 08/2023

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rights...

Virbac : Declaration of the number of shares and voting rights 07/2023

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rights...

Virbac : Declaration of the number of shares and voting rights 06/2023

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rights...

Virbac : Declaration of the number of shares and voting rights 05/2023

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rights...

Virbac : Declaration of the number of shares and voting rights 04/2023

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rights...

Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference…

For more information, please contact: For more information, please contact: Orexo AB (publ.) About Orexo Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are...

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK and LONDON, Sept.05, 2023(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced the company has received written notification from Nasdaq that it has regained compliance with the minimum bid price requirement. The notification of compliance is a result of Akari's American Depository Shares (ADSs) having a closing bid price of $1.00 per share or greater for...

uniQure Announces FDA Clearance of Investigational New Drug Application…

Clinical trial initiation expected in the fourth quarter of 2023 uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-260, the Company's gene therapy candidate for refractory mesial temporal lobe epilepsy ( MTLE ). AMT-260 comprises an AAV9 vector that locally delivers two...

ADC Therapeutics to Participate in September Investor Conferences

Details of the events are as follows: Morgan Stanley Global Healthcare Conference - fireside chat on Monday, September 11th from 2:15 p.m. – 2:45 p.m. ETCantor Global Healthcare Conference - fireside chat on Wednesday, September 27th from 4:45 p.m. – 5:15 p.m. ET Live webcasts of the fireside chats will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast will be available for...

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment…

AC Immuneto Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023Lausanne, Switzerland,September 05 ,2023– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will present a corporate overview and participate in one-on-one investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference, taking place...

Zenas BioPharma Announces Strategic License and Collaboration Agreement with…

Collaboration furthers Zenas' vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb's long-standing expertise in immune-mediated diseasesZenas will receive a $50 million up-front cash payment and an equity investment from Bristol Myers Squibb, along with additional potential milestone-based payments and royalties in the licensed territory WALTHAM, Mass., Sept.05, 2023(GLOBE NEWSWIRE) -- Zenas BioPharma, a global...

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT AUGUST 2023

Accumulated revenue for January – August 2023 increased by 22 % to SEK 1078.8 (886.3) million. Accumulated revenue for January –August 2023increased by 22 % toSEK 1078.8(886.3) million. Revenues were distributed as follows: Countries in regions:-The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &West...

Alchemab Therapeutics CEO to Present at Wells Fargo 2023 Healthcare Conference

The webcast will be archived for 90 days following the live presentation. The webcast will be archived for 90 days following the live presentation. About Alchemab Alchemab studies the unique antibody response of resilient individuals to develop drugs based on naturally derived antibodies to prevalent, hard-to-treat diseases which do not have disease modifying therapies. Alchemab's platform integrates data mining of patient-derived immune responses with the latest, multi-disciplinary...

ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9. The ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology. ERS founder, Dr.Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9. The ERS patent portfolio is thedefinitive collection of proprietary rights to this gene editing technology. AlgenScribe, headquartered inNice, is a biotechnology company...

Six companies enter BioInnovation Institute's Venture House program receiving…

To support product innovation and ecosystem growth, the program consists of four executive sprints, each focused on a key development area to help mature the project and ultimately attract further funding. The first sprint focuses on helping companies develop an operational plan, while the following sprints provide training and support in fundraising, partnership, and leadership. To support product innovation and ecosystem growth, the program consists of four executive sprints, each focused…

CIGNA HEALTHCARE LAUNCHES NEW GLOBAL HEALTH BENEFITS PLAN FOR ADULTS AGED 60+

In addition to a range of health, well-being, and preventive care services, the 'Cigna Healthcare Global Plan for Seniors' provides essential coverage for hospital stays, inpatient and outpatient mental health treatment, and vaccinations. Medical and pharmacy care for hypertension, type 2 diabetes, glaucoma, arthritis, joint or back pain, and osteoporosis/osteopenia can also be included. There is no age limit, ensuring people are covered for as long as needed. Key benefits also include: In...

European Wellness and Heidelberg University Revolutionize Down Syndrome…

"Individualized assessment of neuroanatomical landmarks and cognitive skills is paramount for developing effective intervention strategies," commented Heidelberg University's Head of Neuroanatomy, Prof. Dr. Thomas Skutella. "Individualized assessment of neuroanatomical landmarks and cognitive skills is paramount for developing effective intervention strategies," commented Heidelberg University's Head of Neuroanatomy, Prof. Dr. Thomas Skutella. A second study, published in…

Sectra's three-month interim report 2023/2024: Record-high order bookings

Comments from Torbjörn Kronander, President and CEO of Sectra AB"The first quarter was characterized by significant trust shown by customers in both secure communication and medical imaging IT. We are experiencing a turnaround in secure communication, with high demand and deliveries. We also passed important milestones in the transition to cloud-based solutions for medical diagnostic imaging. These successes demonstrate the value we provide for our customers and that our long-term…

ACM Biolabs Announces Positive Topline Results from a Phase I Trial of…

The trial, which was conducted in thirty-six subjects at six sites in Australia, showed that the vaccine candidate was safe and well-tolerated at the recommended dose level for both standard intramuscular injection as well as mucosal delivery. Promising early immunogenicity data indicate that the intramuscular vaccine initiated a broadly active antibody response targeting previous variants as well as currently circulating omicron strains. The trial, which was conducted in thirty-six subjects…

Signia Introduces Hearing Aids That Tackle the Most Difficult Challenge for…

Signia Integrated Xperience is introducing the world's first hearing aid that identifies and locks on to the voice of every person in a conversation, enhancing their speech and reducing background noise. Signia Integrated Xperience is introducing the world's first hearing aid that identifies and locks on to the voice of every person in a conversation, enhancing their speech and reducing background noise. Conversations are essential to our well-beingConversations and social interactions...

Beactica Therapeutics announces the selection of BEA-17 as a preclinical…

"We are thrilled to announce the selection of BEA-17 as a preclinical candidate. Reaching this remarkable milestone is a major achievement, as the vast majority of programmes fail at the preclinical stage." said Dr Per Källblad, CEO of Beactica Therapeutics. "The selection of this molecule reflects our aim to test this new approach in humans as quickly as possible." "We are thrilled to announce the selection of BEA-17 as a preclinical candidate. Reaching this remarkable…

Crossject reports successful completion of European and U.S. audits for…

Press Release Crossject reports successful completion of European and U.S. audits formanufacturing of ZENEO® Midazolam for epilepticseizures ISO 13485 certification renewed for manufacturing sites at Gray and DijonFrench Health Agency upgrades GMP certification to commercial useU.S. audit readiness of Crossject Dijon and Gray manufacturing sites for a potential FDA audit Dijon, France , September 5, 2023 -- Crossject (ISIN: FR0011716265; Euronext:...

Altri Comunicati